A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Mustafa Khasraw, MD
Duke University
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of California, San Francisco
San Francisco, California, United States
Recruiting - Saint Luke'S Cancer Institute
Kansas City, Missouri, United States
Active, not recruiting - Duke University
Durham, North Carolina, United States
Mustafa Khasraw, MDRecruiting - Huntsman Cancer Institute
Salt Lake City, Utah, United States
Recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 21 Mar 2024
- Primary completion
- 1 Jan 2028
- Completion
- 1 Jan 2028
- Last update posted
- 21 Apr 2026
- Registered enrollment
- 80
- Registry id
- NCT06069726
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.